Publicação
Vaccines against Neisseria meningitidis serogroup B strains – What does genomics reveal on the Portuguese strain’s coverage
| dc.contributor.author | Bettencourt, Célia | |
| dc.contributor.author | Nogueira, Paulo | |
| dc.contributor.author | Gomes, João Paulo | |
| dc.contributor.author | Simões, Maria João | |
| dc.date.accessioned | 2023-03-21T16:13:02Z | |
| dc.date.available | 2023-03-21T16:13:02Z | |
| dc.date.issued | 2022-08-05 | |
| dc.description.abstract | In Portugal, Neisseria meningitidis serogroup B (MenB) is the most common serogroup causing invasive meningococcal disease. To protect against MenB disease two protein based MenB vaccines are available in Portugal, the 4CMenB that was licenced in 2014 and included in the routine immunization program in October 2020, and the bivalent rLP2086 vaccine licensed in 2017. The aim of this study was to predict the coverage of the 4CMenB and rLP2086 vaccines against Portuguese isolates of Neisseria meningitidis sampled between 2012 and 2019 and to evaluate the diversity of vaccine antigens based on genomic analysis. Whole-genome sequence data from 324 Portuguese Neisseria meningitidis isolates were analysed. To predict strain coverage by 4CMenB and rLP2086, vaccine antigen reactivity was assessed using the MenDeVar index available on the PubMLST Neisseria website. This study included 235 (75.6%) MenB isolates of all invasive MenB strains reported between 2012 and 2019. Moreover, 89 non MenB isolates sampled in the same period, enrolling 68 from invasive disease and 21 from healthy carriers, were also studied. The predicted strain coverage of MenB isolates was 73.5% (95% CI: 64.8%-81.2%) for 4CMenB and 100% for rLP2086. Predicted strain coverage by 4CMenB in the age group from 0 to 4 years old, was 73.9%. Most of MenB isolates were covered by a single antigen (85.4%), namely fHbp (30.3%), P1.4 (29.2%), and NHBA (24.7%). In Portugal, the most prevalent peptides in MenB isolates were: P1.4 (16.2%), NHBA peptide 2 (14.0%), and fHbp peptide 14 (7.2%), from 4CMenB and fHbp peptide 19 (10.6%) from rLP2086. No significant temporal trends were observed concerning the distribution and diversity of vaccine antigen variants. 4CMenB and rLP2086 vaccines showed potential coverage for isolates regardless serogroup. The use of both vaccines should be considered to control possible outbreaks caused by serogroups with no vaccine available. | pt_PT |
| dc.description.abstract | Highlights: Predict strain coverage by 4CMenB and rLP2086 vaccines was assessed using the MenDeVar index; Predicted strain coverage among Portuguese MenB isolates was 73.5% for 4CMenB and 100% for rLP2086; 4CMenB showed potential coverage for serogroup W ST 11 isolates, while rLP2086 displayed potential coverage for all the remaining serogroups. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Vaccine. 2022 Aug 5;40(33):4772-4779. doi: 10.1016/j.vaccine.2022.06.038. Epub 2022 Jun 29. | pt_PT |
| dc.identifier.doi | 10.1016/j.vaccine.2022.06.038 | pt_PT |
| dc.identifier.issn | 0264-410X | |
| dc.identifier.uri | http://hdl.handle.net/10400.18/8595 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Elsevier | pt_PT |
| dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S0264410X22008076?via%3Dihub | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | pt_PT |
| dc.subject | Invasive Meningococcal Disease | pt_PT |
| dc.subject | 4CMenB Vaccine | pt_PT |
| dc.subject | MenDeVar Index | pt_PT |
| dc.subject | Strain Coverage | pt_PT |
| dc.subject | rLP2086 Vaccine | pt_PT |
| dc.subject | Infecções Respiratórias | pt_PT |
| dc.title | Vaccines against Neisseria meningitidis serogroup B strains – What does genomics reveal on the Portuguese strain’s coverage | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 4779 | pt_PT |
| oaire.citation.issue | 33 | pt_PT |
| oaire.citation.startPage | 4772 | pt_PT |
| oaire.citation.title | Vaccine | pt_PT |
| oaire.citation.volume | 40 | pt_PT |
| rcaap.embargofct | Acesso de acordo com política editorial da revista. | pt_PT |
| rcaap.rights | embargoedAccess | pt_PT |
| rcaap.type | article | pt_PT |